InterCure Ltd. has announced the strategic acquisition of Botanico Ltd. (ISHI), enhancing its access to premium U.S. cannabis technologies and brands amidst potential regulatory shifts in the cannabis industry.

Target Information

InterCure Ltd. has announced its strategic acquisition of Botanico Ltd., known as ISHI, a leading premium medical cannabis technology and brand company. This significant acquisition gives InterCure immediate access to advanced cultivation technologies and established partnerships with key American cannabis operators, marking an important milestone in InterCure’s commercial expansion strategy.

ISHI holds an exclusive partnership with a top-tier indoor cultivation facility and employs sophisticated AI-driven systems for cultivation optimization. The company has developed strong relationships with renowned U.S. cannabis brands, such as The Flowery, which boasts a substantial presence in Florida and New York. These partnerships provide ISHI with access to highly sought-after U.S. cannabis genetics and established brand loyalty across multiple markets.

Industry Overview

The U.S. cannabis market is poised for significant growth as regulatory landscapes continue to evolve. With potential changes in cannabis rescheduling being explored by the Trump administration, the market stands at a transformati